<DOC>
	<DOC>NCT01733147</DOC>
	<brief_summary>Will oral supplementation with Omega 3 free fatty acids in obese Barrett's esophagus subjects downregulate pro-neoplastic and pro-inflammatory pathways in the esophagus to anti-inflammatory pathway?</brief_summary>
	<brief_title>Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<criteria>Inclusion Criteria Presence of BE defined as ≥ 1 cm of visible columnar mucosa in the distal esophagus with intestinal metaplasia on histology. Absence of high grade dysplasia or EAC on baseline histology. BMI &gt; 30 kg/m2 or waist circumference &gt; 102 cm in men, &gt; 88 cm in women. Ability to give informed consent. Exclusion Criteria Allergy to ω3 FFAs, fish or shellfish. Presence of high grade dysplasia or cancer on histology. Pregnant and or breastfeeding women Presence of esophagitis on initial endoscopy or symptoms of refractory GERD (heartburn or regurgitation ≥ 2 times a week) indicative of uncontrolled gastroesophageal reflux. Inability to give informed consent. Currently taking Omega3 FFA as prescription. Anticoagulant therapy (Plavix, Warfarin, Coumadin) AST or ALT level &gt; three times upper limit of normal at baseline LDL &gt; 200 mg/dl at baseline. INR &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Barrett's esophagus</keyword>
	<keyword>Obesity</keyword>
	<keyword>Omega-3 fatty acid</keyword>
</DOC>